Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

被引：0
|
作者：
K. H. Chan
R. L. O’Connell
D. R. Sullivan
L. S. Hoffmann
K. Rajamani
M. Whiting
M. W. Donoghoe
M. Vanhala
A. Hamer
B. Yu
R. Stocker
M. K. C. Ng
A. C. Keech
机构：
[1] Royal Prince Alfred Hospital,Department of Cardiology
[2] Sydney Medical School,National Health and Medical Research Council Clinical Trials Centre, Level 6, Medical Foundation Building, K25
[3] The Heart Research Institute,Department of Biochemistry
[4] University of Sydney,Center for Vascular Research, School of Medical Sciences (Pathology) and Bosch Institute
[5] Royal Prince Alfred Hospital,Department of Medical Biochemistry
[6] University of Sydney,Unit of Family Practice
[7] Flinders Medical Centre,Department of Cardiology
[8] Central Finland Central Hospital,Department of Molecular and Clinical Genetics
[9] Nelson Hospital,undefined
[10] Royal Prince Alfred Hospital,undefined
来源：
Diabetologia | 2013年 / 56卷
关键词：
Amputation; Bilirubin; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study; Peripheral arterial disease; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：724 / 736
页数：12
相关论文
共 50 条
  • [21] Erratum to: Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    Michael C. d’Emden
    Alicia J. Jenkins
    Liping Li
    Diana Zannino
    Kristy P. Mann
    James D. Best
    Bronwyn G. A. Stuckey
    Kris Park
    Juha Saltevo
    Anthony C. Keech
    Diabetologia, 2015, 58 : 2200 - 2200
  • [22] Fibroblast Growth Factor 21 and Cardiovascular Outcome Events in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
    Ong, Kwok Leung
    Januszewski, Andrzej S.
    O'Connell, Rachel
    Jenkins, Alicia J.
    Xu, Aimin
    Sullivan, David R.
    Barter, Philip J.
    Hung, Wei Ting
    Keech, Anthony C.
    Rye, Kerry-Anne
    DIABETES, 2014, 63 : A295 - A295
  • [23] Relationship of haptoglobin phenotype and levels with sight-threatening diabetic retinopathy in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in diabetes (FIELD) substudy
    Ong, Kwok Leung
    Januszewski, Andrzej S.
    Francis, Habib
    O'Connell, Rachel L.
    Mangani, Abubakar
    Li, Liping
    Colman, Peter G.
    Sullivan, David R.
    Scott, Russell S.
    Jenkins, Alicia J.
    Keech, Anthony C.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2025, 222
  • [24] Inflammation and Oxidative Stress in Type 2 Diabetes Vascular Complications: Predictive Power and Effects of Fenofibrate in the Fenofibrate Intervention and Event Lowering in Diabetes Study
    Jenkins, Alicia J.
    Whiting, Malcolm
    Sullivan, David
    Best, James D.
    Barter, Philip
    Donoghoe, Mark
    Januszewski, Andrzej S.
    Karschimkus, Connie S.
    Blankenberg, Stefan
    Simes, John
    Scott, Russell
    Laakso, Markku
    Taskinen, Marja-Ritta
    Keech, Anthony C.
    DIABETES, 2011, 60 : A9 - A9
  • [25] Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
    Rajamani, Kushwin
    Colman, Peter G.
    Li, Li Ping
    Best, James D.
    Voysey, Merryn
    D'Emden, Michael C.
    Loakso, Markku
    Baker, John R.
    Keech, Anthony C.
    LANCET, 2009, 373 (9677): : 1780 - 1788
  • [26] EFFECT OF FENOFIBRATE ON AMPUTATION EVENTS IN PEOPLE WITH TYPE 2 DIABETES MELLITUS (FIELD STUDY): A PRESPECIFIED ANALYSIS OF A RANDOMISED CONTROLLED TRIAL
    Rajamani, K.
    Colman, P.
    Li, L.
    Best, J.
    Voysey, M.
    D'Emden, M.
    Laakso, M.
    Baker, J.
    Keech, A.
    INTERNAL MEDICINE JOURNAL, 2011, 41 : 13 - 13
  • [27] Fenofibrate reduces the risk of amputation in type 2 diabetes mellitus patients
    不详
    REVISTA ESPANOLA DE CARDIOLOGIA, 2008, 61 (11):
  • [28] Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    Williams, Kathryn H.
    Sullivan, David R.
    Nicholson, Geoffrey C.
    George, Jacob
    Jenkins, Alicia J.
    Januszewski, Andrzej S.
    Gebski, Val J.
    Manning, Patrick
    Tan, Yong Mong
    Donoghoe, Mark W.
    Ehnholm, Christian
    Young, Simon
    O'Brien, Richard
    Buizen, Luke
    Twigg, Stephen M.
    Keech, Anthony C.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (05): : 783 - 793
  • [29] Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study (vol 57, pg 2296, 2014)
    d'Emden, Michael C.
    Jenkins, Alicia J.
    Li, Liping
    Zannino, Diana
    Mann, Kristy P.
    Best, James D.
    Stuckey, Bronwyn G. A.
    Park, Kris
    Saltevo, Juha
    Keech, Anthony C.
    DIABETOLOGIA, 2015, 58 (09) : 2200 - 2200
  • [30] Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    Scott, Russell
    O'Brien, Richard
    Fulcher, Greg
    Pardy, Chris
    d'Emden, Michael
    Tse, Dana
    Taskinen, Marja-Ruita
    Ehnholm, Christian
    Keech, Anthony
    DIABETES CARE, 2009, 32 (03) : 493 - 498
12345